Merck & Co., Inc. (MRK) Operating Margin: 27.59%
Is Merck & Co., Inc.’s operating margin high or low?
Merck & Co., Inc.'s operating margin of 27.59% is 15% above its 5-year average of 23.98%, near the high end of its 5-year range (4.91%–36.17%).
The operating margin for Merck & Co., Inc. (MRK) is 27.59% as of Wednesday, June 10, 2026. It is below its 12-month average by 18.47% (33.84%).
MRK Operating Margin Chart
MRK Average Operating Margin Chart
MRK Current vs Average Operating Margin Chart
MRK Operating Margin Metrics
OPERATING MARGIN
27.59%
OPERATING MARGIN AVG TTM
33.84%
OPERATING MARGIN AVG 3Y
25.86%
OPERATING MARGIN AVG 5Y
23.98%
OPERATING MARGIN AVG 10Y
21.38%
OPERATING MARGIN AVG 15Y
19.70%
OPERATING MARGIN AVG 20Y
20.07%
CURRENT VS TTM AVG
-18.47%
CURRENT VS 3Y AVG
+6.70%
CURRENT VS 5Y AVG
+15.05%
CURRENT VS 10Y AVG
+29.07%
CURRENT VS 15Y AVG
+40.03%
CURRENT VS 20Y AVG
+37.45%
MRK Competitors' Operating Margin
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Merck & Co., Inc. (MRK) | — | 27.59% | 33.84% | 25.86% | 23.98% |
| UnitedHealth Group Incorporated (UNH) | $368.44B | 4.19% | 6.16% | 7.45% | 7.80% |
| AbbVie Inc. (ABBV) | $399.54B | 27.60% | 24.54% | 25.94% | 26.75% |
| Amgen Inc. (AMGN) | $183.75B | 31.63% | 25.38% | 28.78% | 30.08% |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 17.76% | 18.04% | 18.11% | 20.54% |
| Abbott Laboratories (ABT) | $154.66B | 18.17% | 17.21% | 17.41% | 17.71% |
| Gilead Sciences, Inc. (GILD) | $151.21B | 38.26% | 22.76% | 25.11% | 25.54% |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 30.45% | 28.70% | 26.89% | 27.25% |
| Pfizer Inc. (PFE) | $146.36B | 23.45% | 25.29% | 24.23% | 24.05% |
| Danaher Corporation (DHR) | $130.25B | 20.95% | 21.31% | 23.25% | 23.28% |
Operating Efficiency
Gross Margin
75.9%
Operating Margin
27.6%
Merck & Co., Inc. Operating Margin Formula & Definition
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Merck & Co., Inc. Operating Margin FAQ
- What is the operating margin for Merck & Co., Inc. (MRK)?
- The operating margin for MRK stock is 27.59%.
- Is Merck & Co., Inc.'s operating margin high or low?
- Merck & Co., Inc.'s operating margin of 27.59% is 15% above its 5-year average of 23.98%, near the high end of its 5-year range (4.91%–36.17%).
- What is the TTM average operating margin for Merck & Co., Inc. (MRK)?
- The TTM average operating margin for MRK stock is 33.84%.
- What is the 3Y average operating margin for Merck & Co., Inc. (MRK)?
- The 3Y average operating margin for MRK stock is 25.86%.
- What is the 5Y average operating margin for Merck & Co., Inc. (MRK)?
- The 5Y average operating margin for MRK stock is 23.98%.
- What is the 10Y average operating margin for Merck & Co., Inc. (MRK)?
- The 10Y average operating margin for MRK stock is 21.38%.
- What is the 15Y average operating margin for Merck & Co., Inc. (MRK)?
- The 15Y average operating margin for MRK stock is 19.70%.
- What is the 20Y average operating margin for Merck & Co., Inc. (MRK)?
- The 20Y average operating margin for MRK stock is 20.07%.
Merck & Co., Inc. Operating Margin History
| DATE | OPERATING MARGIN |
|---|---|
| 2025-12-31 | 36.17% |
| 2024-12-31 | 31.51% |
| 2023-12-31 | 4.91% |
| 2022-12-31 | 30.84% |
| 2021-12-31 | 27.10% |
| 2020-12-31 | 13.36% |
| 2019-12-31 | 20.26% |
| 2018-12-31 | 21.12% |
| 2017-12-31 | 16.94% |
| 2016-12-31 | 13.81% |
| 2015-12-31 | 19.11% |
| 2014-12-31 | 15.82% |
| 2013-12-31 | 17.41% |
| 2012-12-31 | 20.90% |
| 2011-12-31 | 18.68% |
| 2010-12-31 | 7.30% |
| 2009-12-31 | 14.66% |
| 2008-12-31 | 25.51% |
| 2007-12-31 | 23.22% |
| 2006-12-31 | 16.29% |
| 2005-12-31 | 26.62% |
| 2004-12-31 | 29.42% |
| 2003-12-31 | 38.11% |
| 2002-12-31 | 42.38% |
| 2001-12-31 | 43.77% |
| 2000-12-31 | 22.52% |
| 1999-12-31 | 23.21% |
| 1998-12-31 | 23.70% |
| 1997-12-31 | 24.81% |
| 1996-12-31 | 25.14% |
Related Metrics
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis